Cingulate (CING) Receivables - Net (2023 - 2024)

Cingulate's (CING) quarterly Receivables - Net came in at $2247.0 in Q3 2024, down 99.86% on a QoQ basis from $1.6 million in Q2 2024.

Cingulate (CING) Receivables - Net (2023 - 2024) Analysis & Trends

Cingulate (CING) has 2 years of Receivables - Net data on file, last reported at $2247.0 in Q3 2024.

Quarterly Receivables - Net changed N/A year-over-year to $2247.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $2247.0 (changed N/A YoY) and the FY2023 annual result came in at $14622.0, changed N/A from the prior year.
Receivables - Net slipped to $2247.0 in Q3 2024, from $1.6 million in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $1.6 million in Q2 2024 to a low of $2247.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Cingulate	72.85 Mn	72.85 Mn	-

Download Data